文献速递免疫规划卫生政策与健康促进

埃及引入轮状病毒疫苗的影响与成本效果分析

An impact and cost-effectiveness analysis of rotavirus vaccine introduction in Egypt.
PubMed 文献 · Vaccine · 2025-11-27

该研究评估埃及引入三种轮状病毒疫苗产品(ROTARIX、ROTASIIL或ROTIVAC)相比不接种在十年内的潜在影响与成本效果,采用静态队列模型。结果显示接种可预防大量轮状病毒胃肠炎病例、就诊、住院和死亡,但ROTASIIL在政府视角下以1倍人均GDP为阈值具有成本效果的概率为18%。结论认为需降低疫苗价格和/或论证更低的卫生系统配送成本假设,才可能被视为具有成本效果。

要点

  • ROTASIIL在基础分析中占优其他两种产品,但在1倍人均GDP阈值下具有成本效果的概率仅18%。

核心结论

  • 轮状病毒疫苗接种可预防大量轮状病毒胃肠炎病例、就诊、住院和死亡。
  • 要使疫苗被视为政府卫生支出的成本有效使用,需降低疫苗价格和/或论证更低的卫生系统配送成本假设。

研究设计与样本

  • 研究评估埃及引入三种轮状病毒疫苗产品(ROTARIX、ROTASIIL或ROTIVAC)相比不接种在十年内的潜在影响与成本效果。
  • 采用静态队列模型,年龄结构精细分解至5岁以下周龄,从政府视角计算项目成本及接种与不接种下的轮状病毒胃肠炎病例、就诊、住院、死亡和医疗费用。
  • 进行了概率性和确定性不确定性分析。

主要发现

  • 估计可预防超过64%的轮状病毒胃肠炎医疗费用。
  • 在基础分析中,ROTASIIL占优其他两种产品,因其以更低成本产生相同或更好的健康收益,但从政府视角在1倍人均GDP阈值下具有成本效果的概率为18%。
  • 结果对每剂价格和每剂卫生系统配送成本假设高度敏感。

关键数值与推荐

  • 主要结局指标为从政府视角的每避免一个伤残调整生命年的增量成本。
  • 成本效果阈值设定为1倍人均GDP。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rotavirus vaccines have been introduced in several countries, though not in Egypt where domestic vaccine production is a strategic goal. Evidence on the potential costs and consequences of rotavirus vaccination could inform Egypt's vaccine priority-setting. METHODS: We evaluated the potential impact and cost-effectiveness of introducing three alternative products (ROTARIX®, ROTASIIL®, or ROTAVAC®) compared to no vaccination over a ten-year period. The primary outcome measure was incremental cost per disability-adjusted life year averted from a government perspective. We used a static cohort model with a finely disaggregated age structure (weeks of age < 5 years) to calculate the program costs and the number of rotavirus gastroenteritis cases, clinic visits, hospital admissions, deaths, and healthcare costs with and without vaccination. We ran probabilistic and deterministic uncertainty analyses. RESULTS: We estimate that a decade of rotavirus vaccination in Egypt could prevent >11 million RVGE cases, >7 million clinic visits, >700,000 hospital admissions, and > 1400 deaths in children <5 years old. ROTASIIL would have the lowest program cost (US$306 million), followed by ROTAVAC (US$313 million) and ROTARIX (US$400 million). We also estimate that ˃64 % of RVGE healthcare costs could be prevented with rotavirus vaccination. In the base case analysis, ROTASIIL dominated the other two products because it generated the same or better health benefits at lower cost, but it had an 18 % probability of being cost effective at 1 times GDP per capita threshold from the government perspective. The results were highly sensitive to the per-dose price and assumptions about the health system delivery cost per dose. CONCLUSION: Rotavirus vaccination could prevent a substantial number of RVGE cases, visits, hospitalizations and deaths in children. To be considered a cost-effective use of government health spending, the vaccine price would need to be reduced and/or lower health system delivery cost assumptions would need to be justified.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shaheen MNF, Clark A, Zaghlol A, et al. An impact and cost-effectiveness analysis of rotavirus vaccine introduction in Egypt. Vaccine. 2025. PMID: 41314052. doi:10.1016/j.vaccine.2025.128010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。